{ "schemaVersion": "deck-intelligence.v1", "id": "019de077-880d-703f-ad59-c0ee1df8dfeb", "slug": "3a2edb97bafa9f0a0205c3f0e878214f", "title": "Legend Biotech | Investor Presentation Deck | 26 slides", "subtitle": "Legend Biotech · 2025-04", "author": "Legend Biotech", "date": "2025-04-01 00:00:00", "pageCount": 26, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de077-880d-703f-ad59-c0ee1df8dfeb", "slug": "3a2edb97bafa9f0a0205c3f0e878214f", "title": "Legend Biotech | Investor Presentation Deck | 26 slides", "rawTitle": "Legend Biotech | Investor Presentation Deck | 26 slides", "authorId": "legend-biotech", "authorName": "Legend Biotech", "authorDisplay": "Legend Biotech", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2025-04__legend-biotech__investor-pres__3a2edb97.pdf", "sourceUrl": "https://www.slidebook.io/company/legend-biotech/presentation/3a2edb97bafa9f0a0205c3f0e878214f/", "sourceDate": "2025-04-15 00:00:00", "presentationDate": "2025-04-01 00:00:00", "ingestedAt": "2026-04-30 22:17:03.345391+00", "status": "ready", "pageCount": 26, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2025-04__legend-biotech__investor-pres__3a2edb97", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Investor Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 26, "pagesIndexed": 26, "pagesWithImages": 26, "pagesWithMetadata": 26, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 132, "chartCount": 10, "metricSlides": 0, "toolMatches": 7, "documentToolMatches": 0, "frameworkMatches": 6, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "evidence": "The deck follows a structure similar to the Sequoia Pitch, with sections on problem statement, solution, market sizing, competitive advantage, and pipeline.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:46:25.464512+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Problem", "beatId": "953160cd-55b8-42e3-8fe7-a47be848b35f", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem statement is presented on page 5, discussing Multiple Myeloma.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 7, "name": "Solution", "beatId": "c2be2564-70e4-4fbe-9d0d-c79a920b978f", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is introduced on page 7, highlighting CARVYKTI's achievements.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 12, "name": "Market Size", "beatId": "4e1c0e7a-c66e-4e61-afc3-03ef13607276", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The market sizing is discussed on page 12, unlocking the blockbuster global market opportunity.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 16, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 16, "name": "Competition", "beatId": "82114062-2907-4c9d-8f35-f77cc42869e8", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Competition", "slug": "sequoia-pitch-competition", "status": "active", "canonId": "019dd9b8-21bd-7407-8707-bdf217ed9c76", "version": 1, "description": null }, "evidence": "The competitive landscape is presented on page 16, showing CARVYKTI's lead.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "6befefba-5647-4a98-bbe1-2b8634a8df40", "evidence": "The problem statement and geographic map slides emphasize the importance of addressing Multiple Myeloma.", "position": 0, "objective": "Highlight the need for new treatments for Multiple Myeloma", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:46:25.669585+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null, "categoryName": "Vision", "categorySlug": "vision" }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "8de1df4e-d1f5-4611-a876-9b1bcc256860", "evidence": "This slide serves as a cover page with company name and logo.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.137372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0435c7d-0201-4243-9356-0659bd25c494", "evidence": "This slide provides a high-level overview of Legend Biotech's status.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.259383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "facaf798-2c73-442a-ba20-ab0f93fd53f2", "evidence": "This slide serves as a divider for sections in the presentation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.502351+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d8e09a50-bbe3-4591-b3f4-a8670fde4bf3", "evidence": "Frontline: ~52k patients; 2L to 4L: ~80k patients; 5L+: ~22k patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:50:40.421577+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fe0cffd5-2145-4362-a12e-cb4445ebbca8", "evidence": "list/bullet: Ghent, Belgium: Obelisc. Commercial Site for CARVYKTI. Clinical production started Jan 2024 and commercial production started Sept 2024.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:50:40.534209+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7882289d-abb6-4f2a-9f2b-925b1f2ebfdf", "evidence": "table/data: CORE TECHNOLOGIES: CAR-T, NK, γδ-T; PRODUCT PLATFORMS: Autologous, Allogeneic; DISEASE AREAS: Hematologic malignancies, Solid tumors, Autoimmune Diseases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:50:40.759015+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "64276a43-93f5-4e9e-801a-4e7120d6cd79", "evidence": "paragraph/paragraph: Lung Cancer is the Second Most Diagnosed Cancer in the US. And the leading cause of cancer death in both men and women, accounting for ~20% of all cancer deaths.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:50:40.91249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "f6960b55-db7a-4b48-8862-c2309e11ca9f", "evidence": "Frames the disease as a high unmet need with poor survival outcomes.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "before-after-framing" }, { "matchId": "0333b297-3c49-47f8-abfd-0b23e32eac57", "evidence": "Comparing performance of one product against industry peers over time.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" }, { "matchId": "98d5392a-15c7-4076-8dd2-f0489097283b", "evidence": "Use of a world map to categorize regional regulatory status.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "map-spatial" }, { "matchId": "6223eb87-cd39-4226-b5e4-973962230921", "evidence": "The chart maps events and capacity growth over a chronological axis from 1H22 to 2030.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "timeline" }, { "matchId": "eab2b862-67c2-40ab-9a93-61234c7b8b10", "evidence": "Visual timeline of milestones from 2022-2026", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "timeline" }, { "matchId": "10cb1513-f605-4a43-9ae3-16239d08f442", "evidence": "The slide uses a timeline-based progression (Phases) to map clinical assets.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "gantt-chart" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/49CGUBzpJJqSIXXNag6ymINYzO0_QZZeqO4KhklV_Dw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTJlZGI5N2JhZmE5ZjBhMDIwNWMzZjBlODc4MjE0Zi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 11, "componentCount": 3, "textChars": 61, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:54.712+00", "seconds": 2.198, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/1", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-1", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.15, "x": 0.03, "y": 0.05 }, "kind": "image", "text": "Legend Biotech", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:54.712+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "463df054-02cc-4b22-91d4-aca4bd0bccdc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.1, "x": 0.03, "y": 0.53 }, "kind": "paragraph", "text": "APRIL 2025", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:54.712+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "16871d60-6aee-4dca-b644-bc853354792a", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.03, "y": 0.33 }, "kind": "title", "text": "Legend Biotech CORPORATE PRESENTATION", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:54.712+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5e2d999-b7a1-40ee-8178-1c9968e83f0c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "8de1df4e-d1f5-4611-a876-9b1bcc256860", "evidence": "This slide serves as a cover page with company name and logo.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.137372+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/mpSCvr2bLLYtAYDCHMvCsffvVy2nI-y5sXpyJ3P0gYs/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTJlZGI5N2JhZmE5ZjBhMDIwNWMzZjBlODc4MjE0Zi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/DbnMJUXP7zVcmAS6wAs5iQ9sCibXDX0hDRou68mFIDU/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTJlZGI5N2JhZmE5ZjBhMDIwNWMzZjBlODc4MjE0Zi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/NI6sN3NMMg25ScS9Gq6GFkfQlRYhZIngPBJUF4lJFU8/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTJlZGI5N2JhZmE5ZjBhMDIwNWMzZjBlODc4MjE0Zi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 96, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:58.182+00", "seconds": 5.651, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/2", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-2", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.72, "w": 0.86, "x": 0.07, "y": 0.19 }, "kind": "disclaimer", "text": "This presentation has been prepared by Legend Biotech Corporation... [full legal text]", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "840cb02c-e57b-4522-8f1d-c8b89cb34c40", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.22, "x": 0.07, "y": 0.06 }, "kind": "title", "text": "Disclaimer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.182+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bb544ca9-da4d-43f4-9f01-4aeeb2dc981f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "title": "The slide uses a grid layout to present key company metrics and strategic highlights.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 10, "textChars": 367, "nDataPoints": 4, "notes": "The slide uses a grid layout to present key company metrics and strategic highlights.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.247+00", "seconds": 3.718, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/3", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-3", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.2, "x": 0.25, "y": 0.55 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "149dac54-fc73-4af2-bcaf-9d5eae2fd31e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.2, "x": 0.45, "y": 0.19 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf93348d-8237-45dd-96fb-8bba1f785549", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.04, "y": 0.22 }, "kind": "metric", "text": "Pioneer and Leader in CAR-T Therapy Revolution", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d7e316a-54be-49ab-a11c-122fc406ed6a", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.6 }, "kind": "metric", "text": "$1.1B in Cash, Cash Equivalents and Time Deposits", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "64e1f601-3200-480e-b71f-b387732eb444", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.26, "y": 0.22 }, "kind": "metric", "text": "2,600 Employees 450+ Focused on R&D", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f26dcbb-50b1-4618-b1d3-e5efe68d828e", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.22 }, "kind": "metric", "text": "11 Pipeline Programs in Hematologic Malignancies, Solid Tumors, and Autoimmune Diseases", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc07cffe-5093-4934-994b-97a7f5f12edf", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.04, "y": 0.6 }, "kind": "metric", "text": "Stand-alone with End-to-end Capabilities", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7147631-3ad2-4159-817e-4a8cd654c19a", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.48, "y": 0.6 }, "kind": "metric", "text": "Partnerships Johnson & Johnson And Novartis", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9dfbced-2d77-4a4c-adda-759e0275c65d", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.03, "y": 0.94 }, "kind": "source-note", "text": "1. As of December 31, 2024", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd7fa9c8-0834-44fb-b8b0-84ed87d8b1d5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Legend Biotech – Transforming Cancer Care", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.247+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ae8572f-25d4-4fb5-b754-2b01bc99e490", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0435c7d-0201-4243-9356-0659bd25c494", "evidence": "This slide provides a high-level overview of Legend Biotech's status.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.259383+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "evidence", "title": "The slide highlights clinical and commercial milestones for a CAR-T therapy.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 622, "nDataPoints": 1, "notes": "The slide highlights clinical and commercial milestones for a CAR-T therapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:55.075+00", "seconds": 2.642, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/4", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-4", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.27, "x": 0.03, "y": 0.245 }, "kind": "image", "text": "CARVYKTI logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.075+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84afdb3e-5206-41bf-bdb8-8e35b8ccf2ae", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.9, "x": 0.05, "y": 0.37 }, "kind": "list", "text": "First and only CAR-T cell therapy demonstrating superior OS vs SoC in Multiple Myeloma; >5,000 patients treated worldwide; 2nd line launching as we approach blockbuster status; Strongest CAR-T launch to date driven by commercial and manufacturing execution; International Myeloma Working Group (IWMG) recommended using CAR-T therapy ahead of bi-specifics", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.075+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5cf28d30-981c-476e-83f4-833ba226a43c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.7, "x": 0.03, "y": 0.95 }, "kind": "source-note", "text": "1. L.J. Costa et al. “International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.” Leukemia; https://doi.org/10.1038/s41375-024-02482-6", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.075+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef4df8ea-ebdf-4d20-bf22-aded151729dd", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Proven Leader on the Path to Cure", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.075+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c02de8b2-6bd9-4dc0-a938-6e5d4468269c", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "CARVYKTI®", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.075+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f64e7252-a7d6-4e63-b974-983d69ea3394", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 5, "type": "tension", "title": "Includes Kaplan-Meier survival curve and associated table for refractory patient groups.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 8, "textChars": 628, "nDataPoints": 10, "notes": "Includes Kaplan-Meier survival curve and associated table for refractory patient groups.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:55.944+00", "seconds": 3.496, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/5", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-5", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.42, "x": 0.55, "y": 0.08 }, "kind": "callout", "text": "POOR SURVIVAL OUTCOMES IN MULTIPLE REFRACTORY MM Median OS < 12 months in patients refractory to anti-CD38, ≥ 1 PI(s) and / or ≥ 1 IMiD(s)", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b03ab9cd-64f4-4f41-8ac4-8ee0084ae563", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.42, "x": 0.55, "y": 0.45 }, "kind": "chart", "text": "Kaplan-Meier survival curve", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "396adbd8-55ad-48e5-b68b-5f16e08e4e65", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.33, "x": 0.12, "y": 0.55 }, "kind": "metric", "text": "187,952 NEW CASES WORLDWIDE IN 2022", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b04b4444-0c18-4014-a258-dae3b31fc64b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.48, "x": 0.03, "y": 0.37 }, "kind": "paragraph", "text": "3RD MOST COMMON BLOOD CANCER accounting for 10% of all hematologic cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5145f27-7cce-4022-818f-4cbb6d954b74", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.95, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival. 1. Leukemia & Lymphoma Society... 2. Globocan 2022... 3. Gandhi UH, et al.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5eaf126-deff-4ea0-888b-5fc782b04657", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.28, "x": 0.69, "y": 0.037 }, "kind": "table", "text": "Median OS for each group: Non-triple-refractory 11.2, Triple-and quad-refractory 9.2, Penta-refractory 5.6", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a19a4516-78e2-4f7d-a381-67a4379b6f3d", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.38, "x": 0.03, "y": 0.15 }, "kind": "title", "text": "Blood Cancer with a High Unmet Need", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "447afe34-fd6e-42c1-930b-f5394be73914", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.35, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Multiple Myeloma", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52a4627c-7958-4cad-a20a-cb7736b2ec90", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f6960b55-db7a-4b48-8862-c2309e11ca9f", "evidence": "Frames the disease as a high unmet need with poor survival outcomes.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 10:47:55.944+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "before-after-framing" } ], "arcBeats": [ { "to": 5, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 5, "name": "Problem", "beatId": "953160cd-55b8-42e3-8fe7-a47be848b35f", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The problem statement is presented on page 5, discussing Multiple Myeloma.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "6befefba-5647-4a98-bbe1-2b8634a8df40", "evidence": "The problem statement and geographic map slides emphasize the importance of addressing Multiple Myeloma.", "position": 0, "objective": "Highlight the need for new treatments for Multiple Myeloma", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:46:25.669585+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "evidence", "function": "illustrate_case", "rawType": "geographic_map", "block": null, "metadata": { "slideType": "geographic_map", "slideTypeCanon": { "name": "Geographic map", "slug": "geographic_map", "status": "active", "canonId": "019de52d-09de-7153-8845-584c1a9d0c83", "version": 1, "description": null }, "function": "illustrate_case", "functionCanon": { "name": "Illustrate case", "slug": "illustrate_case", "status": "active", "canonId": "019de52d-13b4-772c-bb73-1873612a7463", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 7, "textChars": 242, "nDataPoints": 4, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:55.129+00", "seconds": 2.66, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/6", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-6", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.94, "x": 0.03, "y": 0.75 }, "kind": "callout", "text": "Working Together to Realize CARVYKTI’S $5B+ Potential", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5731d2c5-f090-4909-9512-2b4683af35cb", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.82, "y": 0.345 }, "kind": "chart", "text": "50/50", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36862e44-cfe9-4997-b90c-9ac7edec76e3", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.11, "y": 0.345 }, "kind": "chart", "text": "50/50", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d7dcf78-a99b-4739-8aad-ccf1f547b051", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.435, "y": 0.345 }, "kind": "chart", "text": "50/50", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Donut chart", "slug": "donut", "status": "active", "canonId": "019de52d-0006-752c-9528-0fef476b8004", "version": 1, "description": null }, "framework": null }, "subkind": "donut", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6dd30c18-a641-4c48-a09d-0544d673f614", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf5f2701-c8ae-45a4-9c96-d5f932341807", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.03, "y": 0.15 }, "kind": "paragraph", "text": "Worldwide Collaboration and License Agreement to Develop and Commercialize Cilta-cel with J&J, the #1 Global Multiple Myeloma Market Leader", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d99f86e8-047b-4ee7-a065-fb2726a2848b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Legend and J&J Global Collaboration", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.129+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fd1a352-723f-419e-b1d4-ea098d425df9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 6, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "6befefba-5647-4a98-bbe1-2b8634a8df40", "evidence": "The problem statement and geographic map slides emphasize the importance of addressing Multiple Myeloma.", "position": 0, "objective": "Highlight the need for new treatments for Multiple Myeloma", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:46:25.669585+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "evidence", "title": "Includes Kaplan-Meier survival curve data.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 4, "textChars": 591, "nDataPoints": 4, "notes": "Includes Kaplan-Meier survival curve data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:55.603+00", "seconds": 3.05, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/7", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-7", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.45, "x": 0.52, "y": 0.2 }, "kind": "chart", "text": "Kaplan-Meier survival curve showing CARVYKTI vs SOC", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62ab2db1-b1f5-4f9d-b5f2-cf27e8c53b1f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.45, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "One-time infusion significantly prolonged overall survival and improved quality of life. 45% reduction in risk of death with CARVYKTI® vs SOC in patients with lenalidomide-refractory MM after 1–3 prior LOT. Safety profile consistent with previous analysis.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84f895ca-c948-4ed1-9464-12b37985aa46", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "1. Mateos, et al. Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update. 2. San-Miguel J, et al.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa1ce93d-d6d3-4c9e-bbde-e1da83ae2b3a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "CARVYKTI® - First CAR-T in MM to Achieve OS Benefit vs SOC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.603+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ed2278b-a284-4711-941e-f8c5550c3876", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 7, "name": "Solution", "beatId": "c2be2564-70e4-4fbe-9d0d-c79a920b978f", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The solution is introduced on page 7, highlighting CARVYKTI's achievements.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 55, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:54.872+00", "seconds": 2.274, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/8", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-8", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.15, "x": 0.03, "y": 0.05 }, "kind": "image", "text": "LEGEND BIOTECH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:54.872+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eaf882c5-ecd2-487d-92e1-1cb82477a840", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.4, "x": 0.03, "y": 0.24 }, "kind": "title", "text": "MAXIMIZING OUR CARVYKTI MARKET LEADERSHIP", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:54.872+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "839ffd9d-e196-4881-8263-c2d9cdd4e41a", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Section divider", "slug": "section-divider", "status": "active", "bestFor": null, "canonId": "019dd9e1-4c66-707d-8d1f-6e14547134c7", "version": 1, "bodyDocId": null, "description": "A transitional slide marking the start of a new section.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "facaf798-2c73-442a-ba20-ab0f93fd53f2", "evidence": "This slide serves as a divider for sections in the presentation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:50:26.502351+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "evidence", "title": "The chart highlights Carvykti's superior growth curve compared to Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 46, "componentCount": 5, "textChars": 251, "nDataPoints": 6, "notes": "The chart highlights Carvykti's superior growth curve compared to Kymriah, Yescarta, Tecartus, Breyanzi, and Abecma.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:55.835+00", "seconds": 3.05, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/9", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-9", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.4, "x": 0.06, "y": 0.21 }, "kind": "callout", "text": "CARVYKTI® - INDUSTRY LEADING EARLY LAUNCH PERFORMANCE", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6f2c94d-4cf8-4144-b7d5-68f3980d6be9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.5, "y": 0.21 }, "kind": "callout", "text": "FIRST ELEVEN QUARTERS OUTPERFORMING HISTORICAL CAR-T LAUNCHES", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f15a8720-1f7a-44a8-9b36-21bd65bd2155", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "chart", "text": "WORLDWIDE SALES OF CAR-T THERAPIES, BY QUARTER OF LAUNCH (IN $MM)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b52eead7-8cf9-4ba5-9cef-66df6bc22f9c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.04, "y": 0.94 }, "kind": "source-note", "text": "Data Source: Companies' public filings.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ff11259e-b55a-4562-b98c-6bafe5d3c87b", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "A New Standard for CAR-T Launches", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8262b354-13a3-4914-b72b-98407def3e36", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "0333b297-3c49-47f8-abfd-0b23e32eac57", "evidence": "Comparing performance of one product against industry peers over time.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 10:47:55.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "evidence", "title": "The chart uses a stacked bar format to distinguish between U.S. and OUS (Outside U.S.) sales.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 253, "nDataPoints": 26, "notes": "The chart uses a stacked bar format to distinguish between U.S. and OUS (Outside U.S.) sales.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.465+00", "seconds": 3.65, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/10", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-10", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.55, "w": 0.45, "x": 0.04, "y": 0.31 }, "kind": "chart", "text": "CARVYKTI® Net Trade Sales ($MM)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4681095-c616-4d5e-8f99-837e6454370e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.15, "x": 0.51, "y": 0.94 }, "kind": "source-note", "text": "1. Q4 2024 vs Q4 2023\n2. Q4 2024 vs Q3 2024", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe0972d5-d80e-4690-a3fd-2298a64d02c7", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.51, "y": 0.465 }, "kind": "table", "text": "Growth table for U.S., OUS, and Global", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df418e26-aa0c-41fd-a5c9-4062349b48f6", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.55, "x": 0.03, "y": 0.15 }, "kind": "title", "text": "Continued Market Penetration and Earlier Lines of Treatment Represents Significant Opportunity for Continued Growth", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfbbd2d3-52cb-4aab-9062-0d82309eb525", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "CARVYKTI® Uptake Continues", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.465+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67b2a160-e576-4e18-8866-00cf134864ca", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "appendix", "title": "The slide lists specific clinical trial identifiers and study designs for Legend Biotech's pipeline.", "function": "appendix", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 1009, "nDataPoints": 0, "notes": "The slide lists specific clinical trial identifiers and study designs for Legend Biotech's pipeline.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:48:01.874+00", "seconds": 8.889, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/11", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-11", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.78, "x": 0.05, "y": 0.89 }, "kind": "disclaimer", "text": "ASCT, autologous stem cell transplant; DVRd, daratumumab, bortezomib, lenalidomide, dexamethasone; NDMM, newly diagnosed multiple myeloma; VRd, bortezomib, lenalidomide, dexamethasone. 1. Clinicaltrials.gov: NCT04133636. 2. Clinicaltrials.gov: NCT04923893. 3. Clinicaltrials.gov: NCT05257083. CARTITUDE-6 is a collaborative study sponsored by the European Myeloma Network.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0cf5dc07-2478-4ebc-87b9-a84b49cfb6b0", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.03, "y": 0.3 }, "kind": "list", "text": "CARTITUDE-2: Global, multi-cohort study; Phase II open-label study of cilta-cel in various clinical settings; Active, enrolling", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20865a33-8740-4e89-8ed6-e2dccdbe9d5e", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.67, "y": 0.3 }, "kind": "list", "text": "CARTITUDE-6: Global, randomized, registrational study; Phase III open-label study comparing DVRd followed by cilta-cel vs. DVRd followed by ASCT in NDMM patients who are transplant eligible; Enrolling", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "678f5add-e598-4c78-b2b6-01d961b9deb4", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.3, "x": 0.35, "y": 0.3 }, "kind": "list", "text": "CARTITUDE-5: Global, randomized, registrational study; Phase III open-label study of VRd followed by cilta-cel vs. VRd followed by Rd maintenance, in patients with NDMM for whom ASCT is not planned as initial therapy; Enrollment completed", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b42abd1-9cbc-44c1-849e-5828adbf79bb", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.54, "x": 0.03, "y": 0.15 }, "kind": "title", "text": "Another Opportunity to Change the Treatment Paradigm", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d492382-0d8b-43e3-bc46-3e07bca0b276", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.38, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Earlier Line Studies", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.874+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "63340331-8cd7-4f8d-8968-9e33af951cb7", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "resolution", "title": "The slide uses a map-based visualization to link regional regulatory status with patient population data.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 8, "textChars": 549, "nDataPoints": 3, "notes": "The slide uses a map-based visualization to link regional regulatory status with patient population data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:48:01.975+00", "seconds": 8.671, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/12", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-12", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.25, "x": 0.45, "y": 0.645 }, "kind": "callout", "text": "South America\nANVISA³ approval for 2L+ MM", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4c9b3613-fda1-49a0-b3b6-bde0ee274b91", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.22, "x": 0.75, "y": 0.48 }, "kind": "callout", "text": "APAC\nMHLW¹ approval for 4L+ MM", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90c07143-afb2-4a4a-b3af-565dbff9a2df", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.22, "x": 0.64, "y": 0.3 }, "kind": "callout", "text": "Europe\nEC approval for 2L+ MM", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df844a23-bc54-4c16-ba72-8bb9e7b0e586", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.22, "x": 0.4, "y": 0.415 }, "kind": "callout", "text": "North America\nFDA approval for 2L+ MM", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f864dc7f-8b60-4034-96b0-eccdcc72b3c7", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.6, "x": 0.4, "y": 0.2 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49947861-18d3-4184-9454-08398ef272aa", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.38, "x": 0.02, "y": 0.275 }, "kind": "paragraph", "text": "MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR CAR-T THERAPY\nFrontline: ~52k patients\n2L to 4L: ~80k patients\n5L+: ~22k patients", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e2e695c-f688-413d-b11e-f6b608eaa4ad", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.04, "y": 0.92 }, "kind": "source-note", "text": "1. MHLW is the Ministry of Health, Labour and Welfare in Japan. 2. ANVISA is the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária. 2L denotes second-line. 4L denotes fourth-line. 5L+ denotes fifth-line and beyond.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "811dccc8-81e7-4f0f-9c41-dd6110362627", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Unlocking the Blockbuster Global Market Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "acbd1795-9e46-4cc9-a12f-800c614320b2", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d8e09a50-bbe3-4591-b3f4-a8670fde4bf3", "evidence": "Frontline: ~52k patients; 2L to 4L: ~80k patients; 5L+: ~22k patients", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:50:40.421577+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "98d5392a-15c7-4076-8dd2-f0489097283b", "evidence": "Use of a world map to categorize regional regulatory status.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 10:48:01.975+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "map-spatial" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 12, "name": "Market Size", "beatId": "4e1c0e7a-c66e-4e61-afc3-03ef13607276", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The market sizing is discussed on page 12, unlocking the blockbuster global market opportunity.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "setup", "title": "The slide uses a pie chart to show the current split between outpatient and inpatient settings, emphasizing the growth potential for outpatient.", "function": "present_solution", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 450, "nDataPoints": 3, "notes": "The slide uses a pie chart to show the current split between outpatient and inpatient settings, emphasizing the growth potential for outpatient.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.595+00", "seconds": 3.259, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/13", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-13", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.78, "w": 0.44, "x": 0.53, "y": 0.11 }, "kind": "chart", "text": "CARVYKTI Treatment Setting Volume: U.S. (48% Outpatient, 52% Inpatient)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Pie chart", "slug": "pie", "status": "active", "canonId": "019de52c-ffdb-71bb-a800-5c5ab9f1c373", "version": 1, "description": null }, "framework": null }, "subkind": "pie", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.595+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14edab5d-73b7-44f0-8d3b-1f54f1a148b7", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.48, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "Extensive use of CARVYKTI in outpatient setting is a key differentiator; Unique delayed CRS onset allows for outpatient administration; Patients and caregivers prefer to leave the treatment setting; Support hospital infrastructure; Expect majority by 2025.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.595+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "305d4042-3e18-483b-b550-c0d606e38e68", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.08, "y": 0.92 }, "kind": "source-note", "text": "1. CRS - Cytokine release syndrome\n2. ATC - Authorized treatment center", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.595+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e35d1529-4c6a-40d3-95bf-2252ff8ed8a5", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Outpatient Administration: Key Competitive Advantage", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.595+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79e00dea-efca-403e-a560-d7f144ec40a0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "appendix", "title": "The slide uses a two-column layout to categorize facilities by region (US vs EU).", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 13, "textChars": 766, "nDataPoints": 1, "notes": "The slide uses a two-column layout to categorize facilities by region (US vs EU).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.171+00", "seconds": 3.823, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/14", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-14", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.84 }, "kind": "callout", "text": "Current Median Turn Around Time is 32 Days", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4abacee-dbd8-422a-883e-55e4a8f5ba13", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.25, "x": 0.04, "y": 0.27 }, "kind": "image", "text": "Raritan, NJ facility photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e8d53f0-52cc-45f0-a3f5-299fd51c1621", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.25, "x": 0.51, "y": 0.55 }, "kind": "image", "text": "Ghent Obelisc facility photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43fbb5ee-4f02-41fc-a750-cdf7349c333a", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.25, "x": 0.04, "y": 0.55 }, "kind": "image", "text": "Morris Plains, NJ facility photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c6c34c0-619f-4fe1-95ad-bdf2c1ff9e11", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.25, "x": 0.51, "y": 0.27 }, "kind": "image", "text": "Ghent Tech Lane facility photo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d16ef9bb-8bf7-434a-9ba3-b9c3cdba6c3f", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.18, "x": 0.3, "y": 0.27 }, "kind": "list", "text": "Raritan, NJ: US/EU/JP/ROW Launch/Commercial Site for CARVYKTI. GMP Operational. Approval of new Raritan section expected in 2H25.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b0810ed-4992-4e06-b872-125e6c14643f", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.18, "x": 0.77, "y": 0.55 }, "kind": "list", "text": "Ghent, Belgium: Obelisc. Commercial Site for CARVYKTI. Clinical production started Jan 2024 and commercial production started Sept 2024.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6bcf0a47-0870-487f-8f51-a5a022195e23", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.18, "x": 0.77, "y": 0.27 }, "kind": "list", "text": "Ghent, Belgium: Tech Lane. Future Site for CARVYKTI. Clinical production expected in 1Q25 and commercial production expected in 4Q25.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8a90b48b-fcd5-494d-ad6f-172952009f15", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.18, "x": 0.3, "y": 0.55 }, "kind": "list", "text": "Morris Plains, NJ: Novartis CMO Site. Clinical production started July 2024 and commercial production started 1Q25.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0c9dbaa-ec5d-4590-8a32-984792196b47", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.04, "y": 0.22 }, "kind": "paragraph", "text": "US FACILITIES", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "75397756-b1d5-4cf9-b553-1e72a1ed949b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.51, "y": 0.22 }, "kind": "paragraph", "text": "EU FACILITIES", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a06557ce-8cdd-44a6-aefc-78dbde6ae6a1", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.4, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "Expanding to Meet Growing Global Demand", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "489f6bb0-939b-4513-b8ed-d061b2072c18", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Global Manufacturing Footprint", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.171+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b68ac6e-89f3-4ef5-b69e-d2ec3c67da0c", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "fe0cffd5-2145-4362-a12e-cb4445ebbca8", "evidence": "list/bullet: Ghent, Belgium: Obelisc. Commercial Site for CARVYKTI. Clinical production started Jan 2024 and commercial production started Sept 2024.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:50:40.534209+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 14, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The chart is a timeline-based growth curve showing capacity expansion milestones.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 348, "nDataPoints": 2, "notes": "The chart is a timeline-based growth curve showing capacity expansion milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.866+00", "seconds": 3.107, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/15", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-15", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.6, "x": 0.35, "y": 0.15 }, "kind": "chart", "text": "Supply ramp-up curve", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2299f622-4e5c-4d86-96b0-be5fdc6a3c4e", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.6, "x": 0.35, "y": 0.15 }, "kind": "framework", "text": "Timeline of supply milestones", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27b3c150-5817-40f7-a693-c451f3579757", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.04, "y": 0.38 }, "kind": "list", "text": "Aim to double commercial supply in 2025 to achieve: 10,000 annualized doses exiting 2025; 20,000 annualized doses exiting 2027. Initiate commercial production at Tech Lane facility targeted for 2H 2025. New section approval expected in Raritan facility in 2H 2025.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5266be9a-db92-4b92-9a31-f12906452735", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "US and EU CARVYKTI® Supply Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d34edbca-3260-4829-a241-b905206a58f1", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6223eb87-cd39-4226-b5e4-973962230921", "evidence": "The chart maps events and capacity growth over a chronological axis from 1H22 to 2030.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 10:47:56.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 16, "type": "evidence", "title": "The slide uses a timeline to establish market leadership and a list of competitive moats.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 5, "textChars": 490, "nDataPoints": 3, "notes": "The slide uses a timeline to establish market leadership and a list of competitive moats.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.027+00", "seconds": 2.728, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/16", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-16", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.94, "x": 0.03, "y": 0.17 }, "kind": "chart", "text": "Timeline of CARVYKTI milestones from 2022 to 2026", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": null, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99d6cedb-4d6c-4e53-9e53-451e7bfb8ea8", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.03, "y": 0.94 }, "kind": "disclaimer", "text": "1. L.J. Costa et al. “International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.” Leukemia; https://doi.org/10.1038/s41375-024-02482-6", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8c4313e7-7f97-4c0b-983a-87809e37ed57", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.94, "x": 0.03, "y": 0.68 }, "kind": "list", "text": "Manufacturing, Extensive Data, First/Only Approved BCMA, Significant Market Opportunity, IMWG Recommendation, Global Market Availability", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e0209e1c-16b0-464e-8a76-ed4bed2b7a70", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.58 }, "kind": "title", "text": "CARVYKTI Leads Potential Competition by >4 Years", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "048430e9-79ed-49e4-a60b-704e7ca71cfe", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Building Upon CARVYKTI's Leadership Position", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7039dda-8452-4ea8-a39c-108fd49b6e60", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "eab2b862-67c2-40ab-9a93-61234c7b8b10", "evidence": "Visual timeline of milestones from 2022-2026", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 10:47:57.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 16, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 16, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 16, "name": "Competition", "beatId": "82114062-2907-4c9d-8f35-f77cc42869e8", "matchId": "e2293fe9-3941-4877-8012-ef4b6dc3d049", "beatType": { "name": "Competition", "slug": "sequoia-pitch-competition", "status": "active", "canonId": "019dd9b8-21bd-7407-8707-bdf217ed9c76", "version": 1, "description": null }, "evidence": "The competitive landscape is presented on page 16, showing CARVYKTI's lead.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "setup", "function": "front_matter", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 53, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.437+00", "seconds": 1.941, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/17", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-17", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.15, "x": 0.03, "y": 0.05 }, "kind": "image", "text": "LEGEND BIOTECH", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "645cf1df-2ea1-4cd7-8bd2-54accf60c463", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.4, "x": 0.07, "y": 0.24 }, "kind": "title", "text": "BUILDING NEXT GENERATION CAR-T PROGRAMS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.437+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1afd16d8-c81b-4be8-923c-2ea4cdf9dc81", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "resolution", "title": "The slide uses a matrix-like structure to organize clinical trials by phase and therapeutic area, including both autologous and allogeneic therapies.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 379, "nDataPoints": 0, "notes": "The slide uses a matrix-like structure to organize clinical trials by phase and therapeutic area, including both autologous and allogeneic therapies.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.722+00", "seconds": 3.175, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/18", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-18", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.32, "w": 0.94, "x": 0.03, "y": 0.18 }, "kind": "diagram", "text": "Cilta-cel Clinical Studies pipeline showing Phase 1, 2, and 3 trials.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43d7044a-9bb3-4236-bbf5-9e9827c90c64", "parentComponentId": null }, { "bbox": { "h": 0.38, "w": 0.94, "x": 0.03, "y": 0.52 }, "kind": "diagram", "text": "Additional Pipeline Assets showing Preclinical and Phase 1 trials for Autologous and Allogeneic therapies.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90d7194b-0efa-4506-b214-164a91c4911b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.091 }, "kind": "disclaimer", "text": "In collaboration with Janssen... *Phase 1 investigator-initiated trial. ‡IND applications have been cleared by the U.S. FDA. ‡Subject to an exclusive license agreement with Novartis Pharma AG.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53f9c660-088f-4a59-b249-952649363b9e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.25, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Our Pipeline", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a3d30a2f-36ce-4f2a-af37-cfe0ddf36938", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "10cb1513-f605-4a43-9ae3-16239d08f442", "evidence": "The slide uses a timeline-based progression (Phases) to map clinical assets.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 10:47:57.722+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "resolution", "title": "The slide combines a feature-benefit breakdown with a linear process flow.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 511, "nDataPoints": 0, "notes": "The slide combines a feature-benefit breakdown with a linear process flow.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.143+00", "seconds": 2.528, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/19", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-19", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.75, "x": 0.13, "y": 0.645 }, "kind": "diagram", "text": "Antibody Screening Platforms -> Binding Domain Selection and Construct Design -> Pre-clinical Validation -> Clinical Proof of Concept", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.143+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "683b46ec-62ae-4529-b96a-61aa6865b555", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.65, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "Armoring strategy for solid tumors; Antibody screening & engineering; Diverse platform for allogeneic treatments", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.143+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f597300-37b5-4ace-8967-df155a231f77", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.6, "x": 0.03, "y": 0.15 }, "kind": "subtitle", "text": "Potential best-in-class proprietary technology platforms and end-to-end capability", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.143+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90984411-d14f-4e67-a117-d6dfe7813702", "parentComponentId": null }, { "bbox": { "h": 0.52, "w": 0.215, "x": 0.758, "y": 0.08 }, "kind": "table", "text": "CORE TECHNOLOGIES: CAR-T, NK, γδ-T; PRODUCT PLATFORMS: Autologous, Allogeneic; DISEASE AREAS: Hematologic malignancies, Solid tumors, Autoimmune Diseases", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.143+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "157e3431-7164-4a78-8b9f-150f976cec55", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.45, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Our Differentiated R&D Approach", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.143+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7adedf5c-fe9d-4389-8aea-43ead54fa59d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "7882289d-abb6-4f2a-9f2b-925b1f2ebfdf", "evidence": "table/data: CORE TECHNOLOGIES: CAR-T, NK, γδ-T; PRODUCT PLATFORMS: Autologous, Allogeneic; DISEASE AREAS: Hematologic malignancies, Solid tumors, Autoimmune Diseases", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:50:40.759015+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "appendix", "title": "Slide 20 of the deck.", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "sparse", "densityScore": 21, "componentCount": 3, "textChars": 219, "nDataPoints": 0, "notes": "Slide 20 of the deck.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.368+00", "seconds": 2.673, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/20", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-20", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.5, "x": 0.25, "y": 0.29 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54a9ea0a-cf67-4af4-b0a4-2e69ea2f0fde", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.8, "x": 0.1, "y": 0.5 }, "kind": "paragraph", "text": "Legend and Novartis have an exclusive, global license agreement to advance certain DLL3-targeted CAR-T therapies, including LB2102, an investigational therapy for small cell lung cancer.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ca56e494-e8f1-494a-ac55-3b00ce8a8f81", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.6, "x": 0.03, "y": 0.06 }, "kind": "title", "text": "Legend and Novartis Collaboration", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.368+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d2712266-b8cc-40df-9c0a-1eb8b0eb5846", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "tension", "title": "The slide uses a two-column layout to contrast general lung cancer statistics with specific SCLC data.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 506, "nDataPoints": 4, "notes": "The slide uses a two-column layout to contrast general lung cancer statistics with specific SCLC data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.387+00", "seconds": 2.504, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/21", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-21", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.45, "x": 0.5, "y": 0.45 }, "kind": "image", "text": "US: Incidence is ~35,000", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Map", "slug": "map", "status": "active", "canonId": "019de52c-fe4d-77bd-b0a4-d72d58b9e5a4", "version": 1, "description": null }, "framework": null }, "subkind": "map", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe06585a-ae57-4dd8-8fbb-2630941d2556", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.45, "x": 0.5, "y": 0.15 }, "kind": "paragraph", "text": "Small Cell Lung Cancer Accounts for ~15% of all Lung Cancer Diagnoses and in 2 out of 3 people with SCLC have extensive stage disease by time of diagnosis.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10ebde83-feab-4f2c-860d-ced832fa52ed", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.05, "y": 0.28 }, "kind": "paragraph", "text": "Lung Cancer is the Second Most Diagnosed Cancer in the US. And the leading cause of cancer death in both men and women, accounting for ~20% of all cancer deaths.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4c6582e-d6f9-427d-a699-874846f7b99d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.65, "x": 0.03, "y": 0.92 }, "kind": "source-note", "text": "1. American Cancer Society, Key Statistics for Lung Cancer. 2. American Cancer Society, Small Cell Lung Cancer Stages.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5041da2b-87c9-4e39-a719-0458623062af", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.03, "y": 0.14 }, "kind": "title", "text": "A Large Unmet Medical Need", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5cdad903-7bb1-4f31-ac2e-a7fcb50e08e3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Small Cell Lung Cancer", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.387+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "317bc38d-2121-458d-85b1-1631e717bb61", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "64276a43-93f5-4e9e-801a-4e7120d6cd79", "evidence": "paragraph/paragraph: Lung Cancer is the Second Most Diagnosed Cancer in the US. And the leading cause of cancer death in both men and women, accounting for ~20% of all cancer deaths.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:50:40.91249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "resolution", "title": "The slide uses a schematic diagram to illustrate the 'Armored' CAR-T mechanism.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 625, "nDataPoints": 1, "notes": "The slide uses a schematic diagram to illustrate the 'Armored' CAR-T mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:58.33+00", "seconds": 3.442, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/22", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-22", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.53, "w": 0.32, "x": 0.648, "y": 0.24 }, "kind": "image", "text": "Schematic of CAR and Armor mechanism", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "de3a3e51-4d8a-4345-9f85-59be010ebf14", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.5, "x": 0.09, "y": 0.65 }, "kind": "list", "text": "PRECLINICAL & Clinical Development strategy: Well-tolerated in vivo; US IND cleared Nov 2022; Orphan Drug Designation June 2023; Actively recruiting at four sites", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2efbd43f-76c1-4f28-9412-6517b59dcb4c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.09, "y": 0.235 }, "kind": "list", "text": "TARGET: DLL-3, a promising target with prevalent & homogeneous expression in SCLC (~80% positive) and other neuroendocrine tumors; Minimal to no expression in normal tissues", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90d16e9a-f6d0-4a23-a7ef-1d6ff912cc51", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.09, "y": 0.45 }, "kind": "list", "text": "MoA/Scientific Rationale: Tandem humanized binders with high affinity and specificity; An armor overcoming suppressive TME to promote CAR-T cell expansion, persistence and infiltration", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d91dd595-b91a-479c-bf28-753b2e133f2c", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.3, "x": 0.03, "y": 0.14 }, "kind": "paragraph", "text": "For Small Cell Lung Cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20227533-007d-4c85-8f94-9e4189811006", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.8, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "LB2102: Legend Armored CAR-T Targeting DLL-3", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.33+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f88260f5-9e24-414c-8f52-71d2203cbfdd", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 23, "type": "resolution", "title": "Includes a schematic of the CAR-T construct.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 7, "textChars": 759, "nDataPoints": 2, "notes": "Includes a schematic of the CAR-T construct.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:59.381+00", "seconds": 4.302, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/23", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-23", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.3, "x": 0.65, "y": 0.24 }, "kind": "image", "text": "Schematic of CAR-T construct", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4fc55272-6f10-455c-9317-675ba2fda34e", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.55, "x": 0.03, "y": 0.65 }, "kind": "list", "text": "Clinical Development strategy: POC achieved in IIT with 43 patients enrolled. US IND was cleared on June 1, 2022. Orphan Drug Designation was granted by FDA on November 22, 2022. The US clinical trial is actively recruiting at six sites.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9bac49aa-a2a5-416e-8a3c-ea95712004e7", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.03, "y": 0.45 }, "kind": "list", "text": "MoA/Scientific Rationale: LB1908 targets CLDN 18.2 via a proprietary VHH antibody. High selectivity against the closely related CLDN 18.1.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d738017b-5637-4e1d-869e-4f2417918b41", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "TARGET: Claudins (CLDN) are a family of tight junction proteins. CLDN18.2 is expressed in gastric cancer and pancreatic cancer.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "feafbfcb-bcb3-4655-9d53-d784548d98f6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.15 }, "kind": "paragraph", "text": "For gastric cancer, esophageal cancer and pancreatic cancer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d87c226-a6ae-4208-abdc-6082be2fdbb0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.64, "y": 0.92 }, "kind": "source-note", "text": "1 Zhang J, et al. Chin J Cancer Res. 2020 Apr;32(2):263-70. 2 Sahin U,et al. Clin Cancer Res. 2008 Dec 1;14(23):7624-34", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "59dbbb18-4c67-4532-ad06-966699a0b5d3", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.95, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "LB1908 (LCAR-C18S): Legend CAR-T Targeting CLDN18.2", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:59.381+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "188bc056-4ea1-47bf-abd6-757a1f812f4b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 24, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 4, "textChars": 505, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:58.739+00", "seconds": 3.618, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/24", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-24", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.3, "x": 0.35, "y": 0.285 }, "kind": "list", "text": "MANUFACTURING: US - Raritan expansion completion and approval in 2H25; Belgium - Tech Lane to initiate commercial production", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2494315c-6206-422b-b768-407692e76cc5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.02, "y": 0.285 }, "kind": "list", "text": "COMMERCIAL: Increasing demand and deepening penetration into the community; Outpatient program expansion; OS label update", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "388335b4-23f0-46d3-9144-d6f19a6deb91", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.68, "y": 0.285 }, "kind": "list", "text": "CLINICAL: Topline data in CART-5; Advance pipeline programs, advance two programs into IND enabling; Other clinical development milestones, potentially Phase 1 data from GC and DLL-3 programs; Philadelphia R&D site to open", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98bf732e-eced-485c-993a-ab9716075a0f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Upcoming Anticipated Legend Milestones", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:58.739+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2765ee34-fee0-44d1-9ddc-88c3fabe8e6e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 25, "type": "setup", "function": "inspire_vision", "rawType": "thesis_headline", "block": null, "metadata": { "slideType": "thesis_headline", "slideTypeCanon": { "name": "Thesis headline", "slug": "thesis_headline", "status": "active", "canonId": "019de52d-073a-70cb-b9f6-772a597bb5af", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 55, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:56.938+00", "seconds": 1.783, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/25", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-25", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.033, "w": 0.045, "x": 0.226, "y": 0.248 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.938+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d5fbd40-48ad-4238-a94a-73d86b8ca459", "parentComponentId": null }, { "bbox": { "h": 0.104, "w": 0.548, "x": 0.226, "y": 0.248 }, "kind": "title", "text": "CARVYKTI is the proven leader forging the path to cure.", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:56.938+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "efb82a01-b72b-4e0a-9bf0-8a69fb60343e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 25, "from": 3, "loop": { "name": "11_golden_circle", "slug": "11-golden-circle", "status": "active", "bestFor": "Visionary leadership, brand positioning, mission statements", "canonId": "019dd956-6a50-7202-882d-505fcb9922ed", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "description": "Invert the typical pitch by starting with why you exist, rather than what you do", "familyLabel": null }, "matchId": "6b23062f-1e91-4b0d-ab29-cd4f465a9867", "evidence": "The deck presents a clear narrative around CARVYKTI's achievements and future potential, aligning with the Golden Circle framework.", "position": 1, "objective": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:46:25.710258+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 26, "type": "setup", "function": "state_next_steps", "rawType": "closing_ask", "block": null, "metadata": { "slideType": "closing_ask", "slideTypeCanon": { "name": "Closing ask", "slug": "closing_ask", "status": "active", "canonId": "019de52d-0aa4-750f-8aa1-8d622dd99f5c", "version": 1, "description": null }, "function": "state_next_steps", "functionCanon": { "name": "State next steps", "slug": "state_next_steps", "status": "active", "canonId": "019de52d-14ca-70ac-b534-971f458cdf29", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 23, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 10:47:57.693+00", "seconds": 2.352, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de077-880d-703f-ad59-c0ee1df8dfeb/26", "deck": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb", "deckAnchor": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb#slide-26", "deckJson": "/decks/019de077-880d-703f-ad59-c0ee1df8dfeb.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.15, "x": 0.03, "y": 0.05 }, "kind": "image", "text": "Legend Biotech", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.693+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce10a9eb-d4c8-4dc2-bed9-bb88081414dd", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.25, "x": 0.03, "y": 0.4 }, "kind": "title", "text": "THANK YOU", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 10:47:57.693+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a133092-da07-46d3-ad9c-af6f09d29c49", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 5, "to": 5, "label": "Problem", "description": "The problem statement is presented on page 5, discussing Multiple Myeloma." }, { "from": 7, "to": 7, "label": "Solution", "description": "The solution is introduced on page 7, highlighting CARVYKTI's achievements." }, { "from": 12, "to": 12, "label": "Market Size", "description": "The market sizing is discussed on page 12, unlocking the blockbuster global market opportunity." }, { "from": 16, "to": 16, "label": "Competition", "description": "The competitive landscape is presented on page 16, showing CARVYKTI's lead." } ], "loops": [ { "from": 5, "to": 6, "label": "Cost Of Inaction", "description": "Highlight the need for new treatments for Multiple Myeloma" }, { "from": 3, "to": 25, "label": "Golden Circle", "description": "Show how CARVYKTI and Legend Biotech's pipeline align with the why, what, and how of transforming cancer care" } ] }